Biogen has had mixed success in Europe in enforcing its patent on a second medical use of dimethylfumarate for the treatment of multiple sclerosis. In the present Dutch case, an attempt to obtain an injunction against three different generic companies resulted in a counterclaim for revocation of the (Dutch part of the) European patent. Biogen was not able to convince the court of the patent’s validity.
Case date: 22 January 2025
Case number: C/09/639604, HA ZA 22-1028, C/09/639606 , HA ZA 22-1029, C/09/639609, HA ZA 22-1030
Court: District Court of The Hague
A full summary of this case has been published on Kluwer IP Law
________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
